STX Shield Therapeutics plc

0.0402USD3.050 GBp · LSE0.00%Mkt Cap: 43.14M USDP/E: —

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Fera…

Key Statistics

Company
Market Cap43.14M USD
Enterprise Value64.77M USD
Revenue (TTM)58.63M USD
Gross Profit23.04M USD
Net Income (TTM)-17.66M USD
Revenue/Share0.06 USD
Last Price0.0402 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees61
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINGB00BYV81293
Valuation
P/E (Trailing)—
P/E (Forward)10.41
PEG—
EV/EBITDA-11.11
EV/Revenue1.10
P/S0.56
P/B-2.55
EPS (TTM)-0.01 USD
EPS (Forward)0.0029 USD
52W Range
0.03822% of range0.1646
52W High0.1646 USD
52W Low0.0382 USD
Profitability
Gross Margin46.36%
Oper. Margin-6.91%
EBITDA Margin-7.56%
Profit Margin-35.52%
ROE117.10%
ROA-27.07%
ROIC-292.41%
ROCE-66.74%
Growth
Revenue Growth41.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.38M USD
CapEx (TTM)300.00K USD
FCF Margin-5.48%
FCF Yield-7.45%
Net Debt16.56M USD
Net Debt/EBITDA-3.74
Net Debt/FCF—
Balance Sheet
Debt/Equity-2.00
Current Ratio0.75
Quick Ratio0.55
Book Value/Sh-0.01 USD
Cash/Share0.0080 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.2063 USD
Upside (mean)+413.7%
Target Range0.1185 USD – 0.3029 USD
0.1185+413.7% to mean0.3029
# Analysts3
Ownership
Shares Out.1.07B
Float413.82M
Insiders61.50%
Institutions3.28%
Technical
SMA 500.0629 (-36.2%)
SMA 2000.0849 (-52.7%)
Beta1.73
S&P 52W Chg12.00%
Avg Vol (30d)3.08M
Avg Vol (10d)1.78M
Technical Indicators
RSI (14)27.3
MACD-0.5894
MACD Signal-0.5313
MACD Hist.-0.0581
BB Upper0.0827 USD
BB Middle0.0526 USD
BB Lower0.0226 USD
BB Width114.33%
ATR (14)0.0049 USD
Vol Ratio (20d)0.12x

About Shield Therapeutics (LON: STX)

›

Shield Therapeutics (LON: STX) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 61 employees.

The shares were at 3.050 GBp on 19 November 2026, down 55.5% over 52 weeks. Its 52-week range is 2.900 GBp to 12.50 GBp: the price is 75.6% below the high and 5.2% above the low.

Its market capitalisation is 32.76M GBP.

Shield Therapeutics reports return on equity of 117.1%, an operating margin of -6.9% and revenue up 41.6% year over year.

Its debt exceeds its cash by 16.56M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.